

STATEMENT SHOWING PRILIMINARY TECHNICAL EVALUATION FOR T NO 168-3 (GENERAL MEDICINES)					
S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
1	Able Pharma	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for the items: 2, 3, 5, 6, 7, 8 & 9 May not be considered for items S.No. 1 & 4			
	1	1623	Chloramphenicol Ear drops 5ml	Firm submitted product license for Chloramphenicol Ear drops 0.5% w/v APMSIDC not mentioned strength of formulation	Addressed to DME
	2	1426	Clotrimazole Ear Drops 1 percentage W/V in 5ml		May be considered
	3	1431	Gatifloxacin eye Drops 0.3 w/v in 5ml		May be considered
	4	303	Gentamicin Eye Drops IP 0.3 Percentage w/v in 5ml	Submitted license for Ear drops (pg no. 9) Clarification may be obtained from the firm	May not be considered
	5	1819	Homatropine eye Drops 2 percentage 5 ml		May be considered
	6	2458	Loteprednol eye drops 0.5 percentagew/v		May be considered
	7	1660	Ofloxacin ophthalmic solution IP 0.3 Percentagew/v in 5ml		May be considered
	8	1447	Phenylephrine HCL 5 percentage W/V Eye Drops 5 ml		May be considered
	9	2423	Sodium Chloride Eye drops 5percentage 5ml		May be considered
2	Adroit Pharmaceuticals Pvt Limited	Technical Evaluation Remarks by Committee of DCA: Applied 04 items may be considered after verification of the present status of stop order activity issued activity order previously issued by the FDA, MH for the observed deficiencies during the firm inspection carried out on 06.10.2023 (As mentioned the GMP certificate of the firm)			
	1	1424	Chloroxylenol 4.8 percentage plus Terpeno9 percentage 1 plus Ab.alcohol13.1 percentage (Dettol) in 1 liter bottle.		May be considered
	2	1317	Ondansetron Tablets IP 4 mg		May be considered
	3	1913	Povidone Iodine Ointment 5Percentage, 30gm	Subjected to supply of 30gm pack	May be considered
	4	635	Salbutamol Sulphate Tablets IP 2 mg		May be considered
3	AFFLATUS PHARMACEUTICALCAL PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: All the applied products may be considered			
	1	1355	Cefotaxime Sodium Injection IP 1000mg		May be considered
	2	1381	Ceftazidime Injection IP 1gm		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	3	1360	Ceftriaxone Injection IP 1gm		May be considered
4	alkem laboratories ltd	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all products			
	1	1340	Amoxycillin 500mg plus 125mg Potassium Clavulanic Acid Tablets IP		May be considered
	2	1	Ampicillin Injection IP 500 mg / 5 ml		May be considered
	3	1355	Cefotaxime Sodium Injection IP 1000mg		May be considered
	4	1360	Ceftriaxone Injection IP 1gm		May be considered
	5	1317	Ondansetron Tablets IP 4 mg		May be considered
5	Appasamy Ocular Devices (P) Ltd.	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all products			
	1	2701.01	Balanced Salt Solution Ophthalmic Solution 500 ml Pouch		May be considered
	2	1431	Gatifloxacin eye Drops 0.3 w/v in 5ml		May be considered
	3	1660	Ofloxacin ophthalmic solution IP 0.3 Percentage w/v in 5ml		May be considered
	4	2423	Sodium Chloride Eye drops 5percentage 5ml		May be considered
	5	1683	Triamcinalone acetate Injection IP 40mg/ml 1ml vial		May be considered
6	AVENUE REMEDIES INDIA PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: (1) Firm may be considered for items in S.No. 1, 3 to 6 (2) The firm may be considered for items in S.No. 2 & 7 after submission of product approval as per tender document			
	1	203	Digoxin Tablets IP 0.25 mg		May be considered
	2	2130	Rifaximin Ph.Eur Tab 550mg	Submitted approval in BP in pg no.11	May not be considered
	3	2417	Salbutamol MDI inhaler		May be considered
	4	20221106	Tab.Torseamide 10mg		May be considered
	5	20221107	Tab.Torseamide 20mg		May be considered
	6	20221105	Tab.Torseamide 5mg		May be considered
	7	1963	Tamsulosin HCL Capsules 400 mcg	Submitted approval for prolonged release form in pg no.10	May not be considered
7	Bajaj Healthcare Limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all products			
	1	40	Ascorbic Acid Tablets IP (Chewable) 500 mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	13122319	Pancreatin Minimicrospheres equivalent to Pancreatin 300mg capsule		May be considered
	3	2416	Sacubutril plus Valsartan film coated Tablet 50mg	The firm submitted valid mfg license (pg no.14) for Sacubutril sodium-24mg equivalent Sacubutril Valsartan-26mg for film coated tablet but tender specification not mentioned the individual ingredients strength May be considered after amendment of the product specification/strength from the APMSIDC	Addressed to DME
8	BARD INDIA HEALTHCARE PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered after submission of valid WHO-GMP certificate and product (item code:140224092) may be considered			
	1	140224092	Absorbable plant based Microporous polysaccharide hemosphere (MPH) hemostatic powder with bellow container-3G Powder		May be considered
9	Biological E. Limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all products			
	1	2267	Diphtheria Anti Toxin 10000 IU/ 10 ml		May be considered
10	CENTURION REMEDIES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm submitted required documents, the firm may be considered for items in S.No. 1 to 12			
	1	1747	Buspirone Tablets IP 5mg		May be considered
	2	20221102	Cap Calcitrol 0.25mcg		May be considered
	3	203	Digoxin Tablets IP 0.25 mg		May be considered
	4	1856	Levodopa 100mg plus Carbidopa 10mg Tablets I.P		May be considered
	5	140224077	Mometasone Furoate 0.1 percentage plus Salicylic Acid 5 percentage Ointment.5gm		May be considered
	6	1317	Ondansetron Tablets IP 4 mg		May be considered
	7	2171	Oseltamivir Oral Suspension 12mg/ml, 75ml		May be considered
	8	2418	Sertaconazole Nitrate Vaginal Tablets 500 mg (Pessaries)		May be considered
	9	20221104	Tab.Sevelamer Carbonate 400mg		May be considered
	10	20221103	Tab.Sodium bicarbonate 500mg		May be considered
	11	20221106	Tab.Torseamide 10mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	12	1968	Tolterodine Tartrate Capsules 2mg		May be considered
11	CENTURY PHARMALABS INIDA PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: For S.No. 1 may be considered and S.No. 2 may be considered subject to supply of 30gm pack			
	1	1424	Chloroxylenol 4.8 percentage plus Terpeno9 percentage l plus Ab.alcohol13.1 percentage (Dettol) in 1 liter bottle.		May be considered
	2	1913	Povidone Iodine Ointment 5Percentage, 30gm	Provided valid mfg drug license for the said product May be considered subjecting to supply of 30gm pack	May be considered
12	CIPLA LTD	Technical Evaluation Remarks by Committee of DCA: (1) May be considered for the items S.No. 1, 2, 3, 5, 6, 7, 8, 10. (2) May be considered the items S.No. 4, 9 after submission of valid product mfg licenses			
	1	2305	Hydroxy Urea Capsules 500mg		May be considered
	2	1853	Letrozole Tablets 2.5mg		May be considered
	3	1317	Ondansetron Tablets IP 4 mg		May be considered
	4	1906	Oxybutynin Tablets BP 2.5mg	Not produced valid product mfg license	May not be considered
	5	2417	Salbutamol MDI inhaler		May be considered
	6	20221106	Tab.Torseamide 10mg		May be considered
	7	20221107	Tab.Torseamide 20mg		May be considered
	8	20221105	Tab.Torseamide 5mg		May be considered
	9	1963	Tamsulosin HCL Capsules 400 mcg	Submitted valid product license for modified release capsules (Rangop, Sikkim unit) (pg no 18)	May not be considered
	10	1968	Tolterodine Tartrate Capsules 2mg		May be considered
13	Concord Drugs	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all products			
	1	1734	Allopurinol Tablets 100 mg		May be considered
	2	1188	Amikacin Sulphate Injection IP 100 mg in 2 ml Ampoule		May be considered
	3	1	Ampicillin Injection IP 500 mg / 5 ml		May be considered
	4	40	Ascorbic Acid Tablets IP (Chewable) 500 mg		May be considered
	5	1355	Cefotaxime Sodium Injection IP 1000mg		May be considered
	6	1381	Ceftazidime Injection IP 1gm		May be considered
	7	1360	Ceftriaxone Injection IP 1gm		May be considered
	8	1752	Cefuroxime Injection IP 250 mg vial		May be considered
	9	1230	Hydrochlorothiazide Tab 25mg		May be considered
	10	2343	Methyl Prednisolone IP 4mg Tablet		May be considered
	11	482	Norfloxacin Tablets IP 400mg		May be considered
	12	1528	Ofloxacin Tablets IP 200 mg		May be considered
	13	1317	Ondansetron Tablets IP 4 mg		May be considered
	14	577	Prednesolone Tab 10mg		May be considered
	15	1492	Prednesolone Tab 20mg		May be considered
	16	635	Salbutamol Sulphate Tablets IP 2 mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	17	20221106	Tab.Torseamide 10mg		May be considered
	18	20221107	Tab.Torseamide 20mg		May be considered
	19	20221105	Tab.Torseamide 5mg		May be considered
	20	2437	Trypsin and Chymotrypsin Tablets 10 mg (or) 1,00,000 armour Units(AU) of Enzyme activity		May be considered
14	Cyano Pharma Private Limited	Technical Evaluation Remarks by Committee of DCA: The items S.No. 1, 3, 4, 5, 6, 7 may be considered The item S.No. 2 may be considered after obtaining the valid product license for Enteric Coated tablets			
	1	2168	Iron Folic Acid Tablets Large Red Enteric Coated		May be considered
	2	2167	Iron Folic Acid Tablets Small Pink Enteric Coated	Not submitted valid product license for Enteric coated tablet	May not be considered
	3	1528	Ofloxacin Tablets IP 200 mg		May be considered
	4	1317	Ondansetron Tablets IP 4 mg		May be considered
	5	1913	Povidone Iodine Ointment 5Percentage, 30gm		May be considered
	6	564.01	Promethazine Hcl Syrup IP 5 mg / 5 ml in 60ml		May be considered
	7	635	Salbutamol Sulphate Tablets IP 2 mg		May be considered
15	ELIKEM PHARMACEUTICALS PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: The items S.No. 2 & 3 may be considered The item S.No. 1 may not be considered as the firm not submitted product license for film coated tablets			
	1	136	Carbamazepine Tablets IP (Film coated or Extended Release) 100mg	Submitted valid product license for uncoated tablet instead of Film coated tablet (pg no.5)	May not be considered
	2	215	Diazepam Tablets IP 5 mg		May be considered
	3	2271	Donepezil Tablets 5mg		May be considered
16	Enzene Biosciences Limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all products			
	1	140224129	Inj.Cetuximab Solution IV 5mg/ml- 20ml vial		May be considered
17	Eurokem Laboratories Pvt Ltd.	Technical Evaluation Remarks by Committee of DCA: The applied items 01-06 may be considered after submission of valid product mfg licenses			
	1	40	Ascorbic Acid Tablets IP (Chewable) 500 mg	Not submitted valid product mfg license	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	136	Carbamazepine Tablets IP (Film coated or Extended Release) 100mg	Not submitted valid product mfg license	May not be considered
	3	1230	Hydrochlorothiazide Tab 25mg	Not submitted valid product mfg license	May not be considered
	4	482	Norfloxacin Tablets IP 400mg	Not submitted valid product mfg license	May not be considered
	5	1528	Ofloxacin Tablets IP 200 mg	Not submitted valid product mfg license	May not be considered
	6	635	Salbutamol Sulphate Tablets IP 2 mg	Not submitted valid product mfg license	May not be considered
18	FIZIKEM LABORATORIES PVT.LTD	Technical Evaluation Remarks by Committee of DCA: The firm may be considered after submission of valid NCC			
	1	482	Norfloxacin Tablets IP 400mg	May be considered after submission of valid NCC	May not be considered
	2	1528	Ofloxacin Tablets IP 200 mg	May be considered after submission of valid NCC	May not be considered
	3	1317	Ondansetron Tablets IP 4 mg	May be considered after submission of valid NCC	May not be considered
	4	1913	Povidone Iodine Ointment 5Percentage, 30gm	May be considered after submission of valid NCC	May not be considered
	5	577	Prednesolone Tab 10mg	May be considered after submission of valid NCC	May not be considered
19	FRESENIUS KABI ONCOLOGY LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied product			
	1	2276	Paclitaxel USP-100mg Nano particle polymer-based		May be considered
20	Glenmark Pharmaceuticals Ltd	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all products			
	1	140224077	Mometasone Furoate 0.1 percentage plus Salicylic Acid 5 percentage Ointment.5gm		May be considered
	2	140224070	Tacrolimus cream 0.1% 20gm		May be considered
21	GRAMPUS LABORATORIES	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for items in S.No. 1 to 20 after submission of valid latest product approvals			
	1	1734	Allopurinol Tablets 100 mg	Not submitted valid latest product approvals	May not be considered
	2	40	Ascorbic Acid Tablets IP (Chewable) 500 mg	Not submitted valid latest product approvals	May not be considered
	3	1749	Cabergoline Tablets 0.25mg	Not submitted valid latest product approvals	May not be considered
	4	2241	Cilostazole Tablet 100mg	Not submitted valid latest product approvals	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	5	2271	Donepezil Tablets 5mg	Not submitted valid latest product approvals	May not be considered
	6	1230	Hydrochlorothiazide Tab 25mg	Not submitted valid latest product approvals	May not be considered
	7	2343	Methyl Prednisolone IP 4mg Tablet	Not submitted valid latest product approvals	May not be considered
	8	482	Norfloxacin Tablets IP 400mg	Not submitted valid latest product approvals	May not be considered
	9	1528	Ofloxacin Tablets IP 200 mg	Not submitted valid latest product approvals	May not be considered
	10	1317	Ondansetron Tablets IP 4 mg	Not submitted valid latest product approvals	May not be considered
	11	1913	Povidone Iodine Ointment 5Percentage, 30gm	Not submitted valid latest product approvals	May not be considered
	12	1492	Prednesolone Tab 20mg	Not submitted valid latest product approvals	May not be considered
	13	564.01	Promethazine Hcl Syrup IP 5 mg / 5 ml in 60ml	Not submitted valid latest product approvals	May not be considered
	14	20221101	Tab Calcium Acetate 667mg USP	Not submitted valid latest product approvals	May not be considered
	15	20221104	Tab.Sevelamer Carbonate 400mg	Not submitted valid latest product approvals	May not be considered
	16	20221106	Tab.Torseamide 10mg	Not submitted valid latest product approvals	May not be considered
	17	20221107	Tab.Torseamide 20mg	Not submitted valid latest product approvals	May not be considered
	18	20221105	Tab.Torseamide 5mg	Not submitted valid latest product approvals	May not be considered
	19	1963	Tamsulosin HCL Capsules 400 mcg	Not submitted valid latest product approvals	May not be considered
	20	1750	Tranexamic Acid Tablets 500mg	Not submitted valid latest product approvals	May not be considered
22	Grifols India Healthcare Pvt Ltd	Technical Evaluation Remarks by Committee of DCA: Firm may be considered			
	1	2250	Coagulation Factor VIII rF VIII (Recombinant or Freeze Dried) 1000 IU		May be considered
	2	1802.01	Factor VIII (500 IU)		May be considered
	3	1367	Human Albumin Solution I.P. 20 percentage in 100 ml bottle /Bag		May be considered
23	Himalaya Meditek Pvt. Ltd.	Technical Evaluation Remarks by Committee of DCA: Firm may be considered, Products may be considered after submission of valid product approvals			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	1188	Amikacin Sulphate Injection IP 100 mg in 2 ml Ampoule	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	2	1	Ampicillin Injection IP 500 mg / 5 ml	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	3	136	Carbamazepine Tablets IP (Film coated or Extended Release) 100mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	4	1355	Cefotaxime Sodium Injection IP 1000mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	5	1360	Ceftriaxone Injection IP 1gm	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	6	140224042	lnj Methyl Prednisolone 40mg/ml,2m1 Amp	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	7	2343	Methyl Prednisolone IP 4mg Tablet	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	8	1528	Ofloxacin Tablets IP 200 mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	9	1317	Ondansetron Tablets IP 4 mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	10	527.01	Paracetamol Injection 300mg in 2ml	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	11	577	Prednesolone Tab 10mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	12	1492	Prednesolone Tab 20mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	13	2407	Risperidone 0.5mg Tablet	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	14	140224046	Tab.Methotrexate 10mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	15	140224045	Tab.Methotrexate 5mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
	16	1750	Tranexamic Acid Tablets 500mg	Not submitted valid product approval, submitted approvals are of previous licensing perusel May be considered after submission of valid product approvals	May not be considered
24	HINDUSTAN LABORATORIES LIMITED	Technical Evaluation Remarks by Committee of DCA: The firm submitted required documents & may be considered for items in S.No. 1 to 6			
	1	40	Ascorbic Acid Tablets IP (Chewable) 500 mg		May be considered
	2	1424	Chloroxylonol 4.8 percentage plus Terpeno9 percentage l plus Ab.alcohol13.1 percentage (Dettol) in 1 liter bottle.		May be considered
	3	2168	Iron Folic Acid Tablets Large Red Enteric Coated		May be considered
	4	2167	Iron Folic Acid Tablets Small Pink Enteric Coated		May be considered
	5	482	Norfloxacin Tablets IP 400mg		May be considered
	6	1913	Povidone Iodine Ointment 5Percentage, 30gm		May be considered
25	INTAS PHARMACEUTICALS LTD.	Technical Evaluation Remarks by Committee of DCA: (1) May be considered for products S.No. 1 to 18, (2) S.No. 19 may not be considered as the specification of the product is not matching with tender specification			
	1	1747	Buspirone Tablets IP 5mg		May be considered
	2	1789	Disulfiram Tablets 250mg (Uncoated)		May be considered
	3	2271	Donepezil Tablets 5mg		May be considered
	4	1221	Enoxaparin Sodium Injection 40mg Pre-filled syringes		May be considered
	5	1802.01	Factor VIII (500 IU)		May be considered
	6	1367	Human Albumin Solution I.P. 20 percentage in 100 ml bottle /Bag		May be considered
	7	140224103	Inj Human Fibrinogen EP/BP 1G 1000mg/vial		May be considered
	8	1853	Letrozole Tablets 2.5mg		May be considered
	9	1906	Oxybutynin Tablets BP 2.5mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	10	2276	Paclitaxel USP-100mg Nano particle polymer-based		May be considered
	11	2125	Prazosin Tab 5mg		May be considered
	12	2407	Risperidone 0.5mg Tablet		May be considered
	13	2416	Sacubutril plus Valsartan film coated Tablet 50mg		May be considered
	14	140224050	Tab.Nitroglycerin 2.6mg		May be considered
	15	20221104	Tab.Sevelamer Carbonate 400mg		May be considered
	16	20221106	Tab.Torseamide 10mg		May be considered
	17	20221107	Tab.Torseamide 20mg		May be considered
	18	20221105	Tab.Torseamide 5mg		May be considered
	19	1963	Tamsulosin HCL Capsules 400 mcg	Submitted license for Tablets instead of Capsules	May not be considered
26	J.P. INDUSTRIES	Technical Evaluation Remarks by Committee of DCA: (1) The firm submitted required documents & may be considered for items in S.No. 1 to 15 and 17 to 34. (2) For item in S.No. 16 clarity may be taken from the manufacturer (As product approval not matched with tender document) as well as from DME			
	1	1734	Allopurinol Tablets 100 mg		May be considered
	2	40	Ascorbic Acid Tablets IP (Chewable) 500 mg		May be considered
	3	136	Carbamazepine Tablets IP (Film coated or Extended Release) 100mg		May be considered
	4	1690	Carbmazepine Suspension USP 100mg/5ml, in 100ml		May be considered
	5	1295	Chlorpromazine Tablets IP 100 mg		May be considered
	6	2241	Cilostazole Tablet 100mg		May be considered
	7	2244	Clindamycin 1 percentage w/w plus Benzoyl Peroxide 2.5 w/w 15 gms		May be considered
	8	1426	Clotrimazole Ear Drops 1 percentage W/V in 5ml		May be considered
	9	2274	Doxylamine succinate Tablet 25 mg		May be considered
	10	1230	Hydrochlorothiazide Tab 25mg		May be considered
	11	2343	Methyl Prednisolone IP 4mg Tablet		May be considered
	12	1313	Mifepristone Tab. 200mg		May be considered
	13	482	Norfloxacin Tablets IP 400mg		May be considered
	14	1528	Ofloxacin Tablets IP 200 mg		May be considered
	15	1317	Ondansetron Tablets IP 4 mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	16	140224051	Oral Glycerol solution 100ml	Submitted approval for Glycerin IP 98% w/w	May not be considered
	17	1651	Phenytoin sodium Syrup 25mg/5ml 60ml bottle		May be considered
	18	1913	Povidone Iodine Ointment 5Percentage, 30gm		May be considered
	19	577	Prednesolone Tab 10mg		May be considered
	20	1492	Prednesolone Tab 20mg		May be considered
	21	564.01	Promethazine Hcl Syrup IP 5 mg / 5 ml in 60ml		May be considered
	22	2393	Pyridoxine HCL CR Tab. 100mg		May be considered
	23	2421	Sertaconazole Nitrate powder 2 percentage w/w 100gm bottle		May be considered
	24	2418	Sertaconazole Nitrate Vaginal Tablets 500 mg (Pessaries)		May be considered
	25	1256	Sucralfate Sulphate Suspension For Oral Administration Contains 1 G Of Sucralfate Per 10 ml In 100ml Bottle, Amber Colour Pet Bottle		May be considered
	26	20221101	Tab Calcium Acetate 667mg USP		May be considered
	27	140224010	Tab. Cilostazole 50mg		May be considered
	28	20221106	Tab.Torsemide 10mg		May be considered
	29	20221107	Tab.Torsemide 20mg		May be considered
	30	20221105	Tab.Torsemide 5mg		May be considered
	31	1963	Tamsulosin HCL Capsules 400 mcg		May be considered
	32	1750	Tranexamic Acid Tablets 500mg		May be considered
	33	2437	Trypsin and Chymotrypsin Tablets 10 mg (or) 1,00,000 armour Units(AU) of Enzyme activity		May be considered
	34	2440	Zinc Sulphate Dispersible Tablet10mg		May be considered
27	JODAS EXPOIM PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered after submission of valid GMP/WHO GMP certificate & latest Non Conviction Certificate. Product with item code: 1221 may be considered & Item code: 2276 may not be considered			
	1	1221	Enoxaparin Sodium Injection 40mg Pre-filled syringes		May be considered
	2	2276	Paclitaxel USP-100mg Nano particle polymer-based	Submitted license for Albumin bound paclitaxel but the requirement is Nano particle plymer based (pg no.13)	May not be considered
28	JOHNSON AND JOHNSON PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products			
	1	2461	Infliximab 100 mg in 10 ml Vial		May be considered
	2	140224087	Inj.Risperdone 25mg inj		May be considered
29	KONIS PHARMACEUTICALS	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	1188	Amikacin Sulphate Injection IP 100 mg in 2 ml Ampoule		May be considered
	2	1355	Cefotaxime Sodium Injection IP 1000mg		May be considered
	3	1381	Ceftazidime Injection IP 1gm		May be considered
	4	1360	Ceftriaxone Injection IP 1gm		May be considered
	5	1752	Cefuroxime Injection IP 250 mg vial		May be considered
	6	303	Gentamicin Eye Drops IP 0.3 Percentage w/v in 5ml		May be considered
	7	1660	Ofloxacin ophthalmic solution IP 0.3 Percentagew/v in 5ml		May be considered
	8	527.01	Paracetamol Injection 300mg in 2ml		May be considered
30	LUPIN LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products			
	1	2276	Paclitaxel USP-100mg Nano particle polymer-based		May be considered
	2	2130	Rifaximin Ph.Eur Tab 550mg		May be considered
	3	2416	Sacubutril plus Valsartan film coated Tablet 50mg		May be considered
31	MACLEODS PHARMACEUTICALS LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products			
	1	1340	Amoxycillin 500mg plus 125mg Potassium Clavulanic Acid Tablets IP		May be considered
	2	20221102	Cap Calcitrol 0.25mcg		May be considered
	3	1355	Cefotaxime Sodium Injection IP 1000mg		May be considered
	4	1360	Ceftriaxone Injection IP 1gm		May be considered
	5	1528	Ofloxacin Tablets IP 200 mg		May be considered
	6	2416	Sacubutril plus Valsartan film coated Tablet 50mg		May be considered
	7	140224040	Tab.Levothyroxine 12.5mg		May be considered
	8	1750	Tranexamic Acid Tablets 500mg		May be considered
32	MALIK LIFESCIENCES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	1340	Amoxicillin 500mg plus 125mg Potassium Clavulanic Acid Tablets IP		May be considered
33	medopharm	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products			
	1	1474	Sulfadoxine plus Pyrimethamine 500 mg Sulfadoxine plus 25 mg Pyrimethamine Tablets		May be considered
34	MEDOPHARM PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered, Product (Item no. 1340) may be considered after submission of valid product approval			
	1	1340	Amoxicillin 500mg plus 125mg Potassium Clavulanic Acid Tablets IP	Submitted product approval was issued during previous licensing period, not submitted valid product approval May be considered after submission of valid product approval	May not be considered
35	MERCK SPECIALITIES PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products			
	1	140224129	Inj.Cetuximab Solution IV 5mg/ml- 20ml vial		May be considered
36	MICRON PHARMACEUTICALS	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products i.e. S No 1 to 9			
	1	40	Ascorbic Acid Tablets IP (Chewable) 500 mg		May be considered
	2	215	Diazepam Tablets IP 5 mg		May be considered
	3	482	Norfloxacin Tablets IP 400mg		May be considered
	4	1528	Ofloxacin Tablets IP 200 mg		May be considered
	5	1913	Povidone Iodine Ointment 5Percentage, 30gm	Subjected to supply of 30gm pack	May be considered
	6	577	Prednesolone Tab 10mg		May be considered
	7	1492	Prednesolone Tab 20mg		May be considered
	8	140224070	Tacrolimus cream 0.1% 20gm	Subjected to supply of 20gm pack	May be considered
	9	1750	Tranexamic Acid Tablets 500mg		May be considered
37	Mylan Laboratories Limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied product			
	1	2427	Sofosbuvir 400mg plus Valpatasvir 100mg tablets		May be considered
38	NANZ MED SCIENCE PHARMA PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied product i.e. S No 1 to 3			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	1424	Chloroxylenol 4.8 percentage plus Terpeno9 percentage 1 plus Ab.alcohol13.1 percentage (Dettol) in 1 liter bottle.	Subjected to supply of 1Ltr bottle package	May be considered
	2	744	Glutaraldehyde 2 percentage Solution 5 liter can	Subjected to supply of 5 ltr cans package	May be considered
	3	1913	Povidone Iodine Ointment 5Percentage, 30gm	Subjected to supply in 30gm pack	May be considered
39	NESTOR PHARMACEUTICALS LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all applied products i.e. S No 1 to 11			
	1	1340	Amoxycillin 500mg plus 125mg Potassium Clavulanic Acid Tablets IP		May be considered
	2	1	Ampicillin Injection IP 500 mg / 5 ml		May be considered
	3	1355	Cefotaxime Sodium Injection IP 1000mg		May be considered
	4	1360	Ceftriaxone Injection IP 1gm		May be considered
	5	2168	Iron Folic Acid Tablets Large Red Enteric Coated		May be considered
	6	2167	Iron Folic Acid Tablets Small Pink Enteric Coated		May be considered
	7	482	Norfloxacin Tablets IP 400mg		May be considered
	8	1528	Ofloxacin Tablets IP 200 mg		May be considered
	9	1317	Ondansetron Tablets IP 4 mg		May be considered
	10	577	Prednesolone Tab 10mg		May be considered
	11	564.01	Promethazine Hcl Syrup IP 5 mg / 5 ml in 60ml		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
40	NOVARTIS HEALTHCARE PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: May be considered for item in S.No. 1 after submission of WHO-GMP of Foreign company & Form-41			
	1	2416	Sacubutril plus Valsartan film coated Tablet 50mg		May be considered
41	NOVO NORDISK INDIA PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied product i.e. S.No. 1			
	1	140224005	Inj.Basal Insulin Analogues 100 IU/ml		May be considered
42	Reliance life sciences pvt ltd	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for six applied products			
	1	2250	Coagulation Factor VIII rF VIII (Recombinant or Freeze Dried) 1000 IU		May be considered
	2	1802.01	Factor VIII (500 IU)		May be considered
	3	1272	Hepatitis B Immunoglobulin Injection100IU/0.5ml or 1ml		May be considered
	4	1367	Human Albumin Solution I.P. 20 percentage in100 ml bottle /Bag		May be considered
	5	2461	Infliximab 100 mg in 10 ml Vial		May be considered
	6	140224103	Inj Human Fibrinogen EP/BP 1G 1000mg/vial		May be considered
43	REVAT LABORATORIES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for S.No. 1 to 3 products, S.No. 4 may not be considered The firm may be considered after submission of valid GMP certificate			
	1	40	Ascorbic Acid Tablets IP (Chewable) 500 mg		May be considered
	2	482	Norfloxacin Tablets IP 400mg		May be considered
	3	1528	Ofloxacin Tablets IP 200 mg		May be considered
	4	1256	Sucralfate Sulphate Suspension For Oral Administration Contains 1 G Of Sucralfate Per 10 ml In 100ml Bottle, Amber Colour Pet Bottle	Submitted product approval for 1g per 500ml (pg no.9)	May not be considered
44	SAI PARENTERALS LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied 3 products			
	1	1355	Cefotaxime Sodium Injection IP 1000mg		May be considered
	2	1360	Ceftriaxone Injection IP 1gm		May be considered
	3	1221	Enoxaparin Sodium Injection 40mg Pre-filled syringes		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
45	SEEKO BIOTICS	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products ie. S.No 1 to 14			
	1	136	Carbamazepine Tablets IP (Film coated or Extended Release) 100mg		May be considered
	2	1424	Chloroxylenol 4.8 percentage plus Terpeno9 percentage 1 plus Ab.alcohol13.1 percentage (Dettol) in 1 liter bottle.		May be considered
	3	1295	Chlorpromazine Tablets IP 100 mg		May be considered
	4	203	Digoxin Tablets IP 0.25 mg		May be considered
	5	2292	Flunarizine Tablets 10mg		May be considered
	6	1230	Hydrochlorothiazide Tab 25mg		May be considered
	7	2343	Methyl Prednisolone IP 4mg Tablet		May be considered
	8	482	Norfloxacin Tablets IP 400mg		May be considered
	9	1528	Ofloxacin Tablets IP 200 mg		May be considered
	10	1317	Ondansetron Tablets IP 4 mg		May be considered
	11	577	Prednesolone Tab 10mg		May be considered
	12	1492	Prednesolone Tab 20mg		May be considered
	13	2393	Pyridoxine HCL CR Tab. 100mg		May be considered
	14	635	Salbutamol Sulphate Tablets IP 2 mg		May be considered
46	SENSES PHARMACEUTICALS PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products			
	1	1431	Gatifloxacin eye Drops 0.3 w/v in 5ml	Subject to supply of 5ml vial pack	May be considered
	2	2458	Loteprednol eye drops 0.5 percentagew/v		May be considered
	3	1660	Ofloxacin ophthalmic solution IP 0.3 Percentagew/v in 5ml	Subject to supply of 5ml vial pack	May be considered
47	Stanex Drugs & Chemicals Private Limited	Technical Evaluation Remarks by Committee of DCA: The firm may be considered after submission of valid NCC			
	1	1221	Enoxaparin Sodium Injection 40mg Pre-filled syringes		May be considered
	2	2409	Rocuronium Bromide Injection 10mg/ml, 2.5ml Vials		May be considered
48	STRIDE ORGANICS PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for applied products S.No. 1 to 7			
	1	2452	Activated Charcoal IP (powder)		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	2	1340	Amoxicillin 500mg plus 125mg Potassium Clavulanic Acid Tablets IP		May be considered
	3	40	Ascorbic Acid Tablets IP (Chewable) 500 mg		May be considered
	4	2168	Iron Folic Acid Tablets Large Red Enteric Coated		May be considered
	5	2167	Iron Folic Acid Tablets Small Pink Enteric Coated		May be considered
	6	482	Norfloxacin Tablets IP 400mg		May be considered
	7	1256	Sucralfate Sulphate Suspension For Oral Administration Contains 1 G Of Sucralfate Per 10 ml In 100ml Bottle, Amber Colour Pet Bottle		May be considered
49	SUDARSHAN PHARMACEUTICALS PVT LTD	Technical Evaluation Remarks by Committee of DCA: (1) May be considered for the items S.No. 1, 2, 3, 4 (2) May be considered item no. 5 after obtaining the valid product mfg license with required strength			
	1	2168	Iron Folic Acid Tablets Large Red Enteric Coated		May be considered
	2	2167	Iron Folic Acid Tablets Small Pink Enteric Coated		May be considered
	3	482	Norfloxacin Tablets IP 400mg		May be considered
	4	1528	Ofloxacin Tablets IP 200 mg		May be considered
	5	635	Salbutamol Sulphate Tablets IP 2 mg	Not submitted valid product mfg license	May not be considered
50	Syndicate Pharma	Technical Evaluation Remarks by Committee of DCA: (1) The firm may be considered for item in S.No. 1 (2) For items in S.No. 2 & 3 may be considered after submission of product approvals as per tender document			
	1	1913	Povidone Iodine Ointment 5Percentage, 30gm		May be considered
	2	140224061	Silver Sulphadiazine (Nano Crystalline) Cream 0.5 percentage W/W, 20 GM tube	Not submitted product approval as per tender document	May not be considered
	3	1256	Sucralfate Sulphate Suspension For Oral Administration Contains 1 G Of Sucralfate Per 10 ml In 100ml Bottle, Amber Colour Pet Bottle	Not submitted product approval as per tender document	May not be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
51	TABLETS INDIA LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered, Products may be considered after submission of valid product approvals			
	1	140224049	Inj. Multivitamin 10ml	Submitted product approvals was issued during previous licensing period, not submitted valid product approval (pg .n o. 20) May be considered after submission of valid product approval	May not be considered
	2	1314	Neostigmine Injection IP 0.5 mg/ ml in 5ml	Submitted product approvals was issued during previous licensing period, not submitted valid product approval (pg .n o. 20) May be considered after submission of valid product approval	May not be considered
52	TAKEDA BIOPHARMACEUTICALS INDIA PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered			
	1	1367	Human Albumin Solution I.P. 20 percentage in 100 ml bottle /Bag		May be considered
53	TALENT HEALTHCARE	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all applied products S.No. 1 to 7			
	1	1360	Ceftriaxone Injection IP 1gm		May be considered
	2	2343	Methyl Prednisolone IP 4mg Tablet		May be considered
	3	1528	Ofloxacin Tablets IP 200 mg		May be considered
	4	1317	Ondansetron Tablets IP 4 mg		May be considered
	5	20221106	Tab.Torsemide 10mg		May be considered
	6	20221107	Tab.Torsemide 20mg		May be considered
	7	1750	Tranexamic Acid Tablets 500mg		May be considered
54	THE SWASTIKPHARMACEUTICALS	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all applied 3 products			
	1	1424	Chloroxylenol 4.8 percentage plus Terpeno9 percentage l plus Ab.alcohol13.1 percentage (Dettol) in 1 liter bottle.		May be considered
	2	744	Glutaraldehyde 2 percentage Solution 5 liter can		May be considered
	3	1256	Sucralfate Sulphate Suspension For Oral Administration Contains 1 G Of Sucralfate Per 10 ml In 100ml Bottle, Amber Colour Pet Bottle		May be considered
55	THEMIS MEDICARE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all applied 3 products			

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	1	1697	BupivacaineHcl (Spinal)		May be considered
	2	404	Ketamine Hcl Injection IP 50mg / ml in 10-ml Vial		May be considered
	3	1314	Neostigmine Injection IP 0.5 mg/ ml in 5ml		May be considered
56	Unicure India Pvt. Ltd.	Technical Evaluation Remarks by Committee of DCA: The items S.No. 02-10, 12, 16, 17, 19, 21-25, 27, 29, 31, 34 (total 22 items) may be considered The items S.No. 01, 11, 13, 14, 15, 18, 20, 26, 28, 30, 32, 33 (total 12 items) may be considered after obtaining valid product mfg licenses			
	1	1522	ACT Kit for Adults	Not submitted valid prouduct license with required strength (in pg.50 product license with other strength)	May not be considered
	2	1734	Allopurinol Tablets 100 mg		May be considered
	3	40	Ascorbic Acid Tablets IP (Chewable) 500 mg		May be considered
	4	1690	Carbmazepine Suspension USP 100mg/5ml, in 100ml		May be considered
	5	1625	Chloroquine Phosphate Syrup 50 mg / 5 ml in 60ml		May be considered
	6	1295	Chlorpromazine Tablets IP 100 mg		May be considered
	7	215	Diazepam Tablets IP 5 mg		May be considered
	8	203	Digoxin Tablets IP 0.25 mg		May be considered
	9	2271	Donepezil Tablets 5mg		May be considered
	10	1230	Hydrochlorothiazide Tab 25mg		May be considered
	11	1853	Letrozole Tablets 2.5mg	Not produced valid product mfg license (pg no.63)	May not be considered
	12	1856	Levodopa 100mg plus Carbidopa 10mg Tablets I.P		May be considered
	13	2343	Methyl Prednisolone IP 4mg Tablet	Not produced valid product license (pg no.58)	May not be considered
	14	140224077	Mometasone Furoate 0.1 percentage plus Salicylic Acid 5 percentage Ointment.5gm	Not produced valid product mfg license	May not be considered
	15	2351	Naproxen Sodium Tablet 500mg	Not produced valid product mfg license	May not be considered
	16	1528	Ofloxacin Tablets IP 200 mg		May be considered
	17	1317	Ondansetron Tablets IP 4 mg		May be considered
	18	2171	Oseltamivir Oral Suspension 12mg/ml, 75ml	Not produced valid product license (produce product license dt:21/01/2016)	May not be considered
	19	1651	Phenytoin sodium Syrup 25mg/5ml 60ml bottle		May be considered
	20	1913	Povidone Iodine Ointment 5Percentage, 30gm	Not produced valid product mfg license	May not be considered
	21	2125	Prazosin Tab 5mg		May be considered
	22	577	Prednesolone Tab 10mg		May be considered
	23	1492	Prednesolone Tab 20mg		May be considered
	24	564.01	Promethazine Hcl Syrup IP 5 mg / 5 ml in 60ml		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
	25	635	Salbutamol Sulphate Tablets IP 2 mg		May be considered
	26	2421	Sertaconazole Nitrate powder 2 percentage w/w 100grm bottle	Not produced valid product license (produced license dt:03/02/2017 at pg.57)	May not be considered
	27	2418	Sertaconazole Nitrate Vaginal Tablets 500 mg (Pessaries)		May be considered
	28	1256	Sucralfate Sulphate Suspension For Oral Administration Contains 1 G Of Sucralfate Per 10 ml In 100ml Bottle, Amber Colour Pet Bottle	Not produced valid product license (produced license dt:23/11/2013 at pg.55)	May not be considered
	29	1474	Sulfadoxine plus Pyrimethamine 500 mg Sulfadoxine plus 25 mg Pyrimethamine Tablets		May be considered
	30	20221101	Tab Calcium Acetate 667mg USP	Not produced valid product mfg license (pg no.60)	May not be considered
	31	20221103	Tab.Sodium bicarbonate 500mg		May be considered
	32	20221106	Tab.Torseamide 10mg	Not produced valid product mfg license (pg no.61)	May not be considered
	33	1963	Tamsulosin HCL Capsules 400 mcg	Not produced valid product mfg license (pg no.54)	May not be considered
	34	1750	Tranexamic Acid Tablets 500mg		May be considered
57	vins bio products limited	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all applied products S. No. 1 to 2			
	1	2267	Diphtheria Anti Toxin 10000 IU/ 10 ml		May be considered
	2	1681	Rabies Anti serum Injection Immunoglobulin, Equine 300 IU/ml		May be considered
58	Vivimed Labs Limited	Technical Evaluation Remarks by Committee of DCA: The firm may be considered for items in S.No. 1 to 3 after submission of valid/latest product approvals along with manufacturing site address			
	1	1431	Gatifloxacin eye Drops 0.3 w/v in 5ml	Not submitted valid product approval with manufacturing site address May be considered after submission of valid product approval along with manufacturing site address	May not be considered
	2	2421	Sertaconazole Nitrate powder 2 percentage w/w 100grm bottle	Not submitted valid product approval with manufacturing site address May be considered after submission of valid product approval along with manufacturing site address	May not be considered
	3	2418	Sertaconazole Nitrate Vaginal Tablets 500 mg (Pessaries)	Not submitted valid product approval with manufacturing site address May be considered after submission of valid product approval along with manufacturing site address	May not be considered
59	WALLACE PHARMACEUTICALS PVT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all applied products i.e, only one product			
	1	140224117	Tab.Clindamycin 300mg		May be considered

S No	Bidder Name	Item Code	Item Name	Priliminary Remarks	Priliminary Status
60	WILCURE REMEDIES PRIVATE LIMITED	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all applied products i.e, only one product			
	1	1528	Ofloxacin Tablets IP 200 mg		May be considered
61	WOCKHARDT LTD	Technical Evaluation Remarks by Committee of DCA: Firm may be considered for all applied products S.No. 1 to 3			
	1	1631	Human Premixed Insulin Injection IP 30/70 in 10 ml vial		May be considered
	2	140224005	Inj.Basal Insulin Analogues 100 IU/ml		May be considered
	3	1634	Insulin Injection (Soluble) Human Injection IP 40 IU / ml in 10 ml vial		May be considered
<p>Note: All the bidders are here by requested to verify the Provisional Technical Evaluation Report and submit their supporting documents on or before 05.00PM on 17.04.2025 to the email id: tenders.apmsidc@gmail.com with Subject : Reply to T No 168-3 (General Medicines) TEC Report</p>					